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Research letter
The BIOMarkers in Atopic Dermatitis and
Psoriasis (BIOMAP) glossary: developing a
lingua franca to facilitate data harmonization
and cross-cohort analyses
DOI: 10.1111/bjd.20587
DEAR EDITOR, The BIOMarkers in Atopic dermatitis and Psoriasis
(BIOMAP) is a large European consortium aiming to advance
personalized medicine for atopic dermatitis and psoriasis by
identifying biomarkers that predict therapeutic response and
disease progression. BIOMAP brings together clinicians,
researchers, patient organizations and pharmaceutical industry
partners, and encompasses data from over 60 individual studies,
including randomized clinical trials, population-based cohorts
and deeply phenotyped disease registries. The curation and har-
monization of data and biosamples from these established stud-
ies will facilitate cross-cohort clinical and molecular analyses,
increasing the potential to identify small-effect estimates and to
better stratify disease subtypes. This research letter serves to dis-
seminate BIOMAP’s pathway to data harmonization and will
inform future collaborative research endeavours.
Pooling data from diverse studies presents inherent challenges.
Each study has different methodologies, research objectives and
outcomes. Data harmonization improves the comparability of
existing studies by converting similar variables to a common for-
mat and creating ‘harmonized datasets’, which can be used for
cross-cohort analyses. Figure 1 outlines how BIOMAP follows
existing data harmonization guidelines,1 ensuring that clinically
appropriate and meaningful conclusions can be drawn.
BIOMAP’s objectives were outlined in the project proposal (step
0). During protocol development, a list of variables pertinent to
BIOMAP’s key research questions was devised. These predefined
‘BIOMAP categories’ included clinical phenotypes, disease associa-
tions, environmental/lifestyle factors, treatments and outcome
measures. Next, a detailed mapping exercise was performed to
explore what data were available in a subset of the studies underpin-
ning BIOMAP. This involved the custodians of individual study
datasets assigning a BIOMAP category to each variable in their
study’s data dictionary. Annotated data dictionaries were assimilated
into a clinical ‘metadata catalogue’ indexed according to the BIO-
MAP categories, generating a high-level overview of the clinical
variables recorded in this sample of BIOMAP studies (step 1). The
metadata catalogue identified similarities and discrepancies between
studies, and formed the foundation of the BIOMAP glossary.
The BIOMAP glossary defines a list of core variables, using
harmonized terminology and data format (step 2), and will be
used to create harmonized datasets. The Glossary Development
Team comprised clinical, bioinformatics, biostatistics and labo-
ratory expertise, and discussed the potential contents of the
glossary (11 members, representing five BIOMAP organiza-
tions). Discussions were informed by the metadata catalogue,
literature reviews and existing harmonization initiatives,
including the TREatment of ATopic eczema (TREAT) Registry
Taskforce,2 Harmonising Outcome Measures for Eczema3 and
the International Psoriasis Council.4
A BIOMAP webinar introduced data harmonization to the
wider BIOMAP consortium, illustrating the fundamental role
the glossary would play in downstream BIOMAP analyses. Fol-
lowing the webinar, glossary stakeholders were identified
(n = 67, including work-package leaders, dataset custodians,
clinicians and analysts from 28 BIOMAP organizations).
A draft glossary was circulated to the glossary stakeholders
who refined and approved the finalized glossary through a ser-
ies of three interactive Zoom meetings. Following group discus-
sion, any amendments to the proposed glossary were approved
or rejected through anonymous polling, using in-built Zoom
functionality (30 polls). The outcome of voting was accepted
with a simple majority (median agreement 100%; range 57–
100) and the BIOMAP glossary version 1.0 was finalized.
Primary datasets are being transformed to conform to the
content and structure of the BIOMAP glossary, creating har-
monized datasets (step 3). Iterative discussions between each
dataset custodian and the harmonization bioinformaticians cul-
minate with a dataset-specific mapping document specifying
how individual variables will be transformed to the glossary-
defined dataset, thus ensuring accurately harmonized data
(step 4). Harmonized datasets are made available on a secure,
centralized and access-controlled data platform (step 5). Har-
monized clinical datasets complement a carefully curated
bioresource of archived and newly obtained biospecimens,
which will be used for multiomic profiling of skin and blood.
The structure of the BIOMAP glossary was inspired by the
internationally recognized Observational Medical Outcomes
Partnership (OMOP) Common Data Model (CDM).5 The
OMOP CDM adopts existing vocabularies, such as SNOMED
Clinical Terms,6 and was developed to implement standardized
analytical approaches on large observational datasets. During
glossary development, deviations from the OMOP CDM were
made where existing variables were not represented in the
OMOP-defined terminology or where dermatological research
required additional granularity (e.g. detailed information
regarding phototherapy). The OMOP CDM tabular structure
was adjusted to match BIOMAP analysts’ requirements. Full
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compatibility with the OMOP CDM is a priority for further
development of the glossary.
The publicly available BIOMAP glossary may benefit investiga-
tors beyond the BIOMAP consortium who could prospectively
align future studies with the glossary’s clinical variables, thus
facilitating comparative analyses.7 Published dermatological
research using OMOP approaches is currently limited.8 Coopera-
tion between BIOMAP and OMOP, leading to the incorporation
of BIOMAP customizations into the OMOP CDM is an appealing
prospect. Collaboration could further enhance the potential for
dermatological research using large observational datasets.
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Figure 1 The pathway to data harmonization of BIOMarkers in Atopic dermatitis and Psoriasis (BIOMAP) studies. (Left) Proposed steps for
retrospective data harmonization (adapted from the Maelstrom guidelines).1 (Right) Implementation of these steps for data harmonization in
BIOMAP. Overlapping boxes represent steps running concurrently. Following finalization of the BIOMAP glossary (step 2), harmonization of
individual study datasets started in a pragmatic and prioritized manner, based on the availability of data and proposed cross-cohort analyses.
Quality assurance (step 4) is integrated with step 3 in our harmonization pipeline, expediting the availability of harmonized datasets for cross-
cohort analyses.
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